New-onset atrial fibrillation

New-onset atrial fibrillation (AF) represents the first detectable episode of the condition, spanning paroxysmal, persistent, or permanent forms. Diagnosis requires a comprehensive clinical history and physical examination, confirmed by a 12-lead or single-lead ECG showing irregular RR intervals and absent P waves. Modern diagnostic tools, including smartwatch-based photoplethysmography, demonstrate high sensitivity and specificity, as evidenced by the WATCH-AF and Apple Heart trials. Management centers on three pillars: ventricular rate control, restoration of sinus rhythm, and thromboembolic stroke prevention. Direct oral anticoagulants (DOACs) are now preferred over Warfarin due to their superior pharmacokinetic profiles and reduced monitoring requirements. Clinical pitfalls often involve the misinterpretation of subclinical AF burden and the failure to address underlying comorbidities like heart failure or thyrotoxicosis. Long-term success necessitates lifestyle modifications, such as smoking cessation and the avoidance of binge drinking, to mitigate recurrence and improve patient outcomes.